# BNB Plus Corp.: financial statements, quarterly

BNBX · OTC · CIK 744452 · [Financials](/sectors/financials.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/bnbx.md) · [Financials](/companies/bnbx/financials.md) · [Filings](/companies/bnbx/filings.md) · [Insiders](/companies/bnbx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bnbx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.8 d](/filings/0001410578-24-002100.md) | [0.9](/filings/0001410578-25-000126.md) | [0.9](/filings/0001410578-25-001320.md) | [0.5](/filings/0001410578-25-001814.md) | [0.5 d](/filings/0001104659-25-123342.md) | [0.9](/filings/0001104659-26-014324.md) | [0.8](/filings/0001104659-26-062596.md) | [0.3](/filings/0001104659-26-095910.md) | [0.2 d](/filings/0001104659-25-123342.md) | [0.6](/filings/0001104659-26-014324.md) | [1.0](/filings/0001104659-26-062596.md) | [0.6](/filings/0001104659-26-095910.md) |
| Cost of revenue | $m | [0.7 d](/filings/0001410578-24-002100.md) | [0.7](/filings/0001410578-25-000126.md) | [0.6](/filings/0001410578-25-001320.md) | [0.2](/filings/0001410578-25-001814.md) | [0.3 d](/filings/0001104659-25-123342.md) | [0.3](/filings/0001104659-26-014324.md) | [0.4](/filings/0001104659-26-062596.md) | [0.3](/filings/0001104659-26-095910.md) | [0.4 d](/filings/0001104659-25-123342.md) | [0.3](/filings/0001104659-26-014324.md) | [0.2](/filings/0001104659-26-062596.md) | [0.2](/filings/0001104659-26-095910.md) |
| Gross profit | $m | [0.1 d](/filings/0001410578-24-002100.md) | [0.2](/filings/0001410578-25-000126.md) | [0.3](/filings/0001410578-25-001320.md) | [0.2](/filings/0001410578-25-001814.md) | [0.2 d](/filings/0001104659-25-123342.md) | [0.6](/filings/0001104659-26-014324.md) | [0.4](/filings/0001104659-26-062596.md) | [0.0](/filings/0001104659-26-095910.md) | [(0.2) d](/filings/0001104659-25-123342.md) | [0.3](/filings/0001104659-26-014324.md) | [0.8](/filings/0001104659-26-062596.md) | [0.4](/filings/0001104659-26-095910.md) |
| Research and development | $m | [0.9 d](/filings/0001410578-24-002100.md) | [0.9](/filings/0001410578-25-000126.md) | [0.9](/filings/0001410578-25-001320.md) | [0.9](/filings/0001410578-25-001814.md) | [0.8 d](/filings/0001104659-25-123342.md) | [1.0](/filings/0001104659-26-014324.md) | [0.8](/filings/0001104659-26-062596.md) | [0.8](/filings/0001104659-26-095910.md) | [3.4 d](/filings/0001104659-25-123342.md) | [0.5](/filings/0001104659-26-014324.md) | [0.4](/filings/0001104659-26-062596.md) | [0.2](/filings/0001104659-26-095910.md) |
| Selling, general and administrative | $m | [3.3 d](/filings/0001410578-24-002100.md) | [3.1](/filings/0001410578-25-000126.md) | [3.0](/filings/0001410578-25-001320.md) | [2.6](/filings/0001410578-25-001814.md) | [2.6 d](/filings/0001104659-25-123342.md) | [2.6](/filings/0001104659-26-014324.md) | [2.9](/filings/0001104659-26-062596.md) | [2.9](/filings/0001104659-26-095910.md) | [2.4 d](/filings/0001104659-25-123342.md) | [13.3](/filings/0001104659-26-014324.md) | [2.6](/filings/0001104659-26-062596.md) | [2.1](/filings/0001104659-26-095910.md) |
| Operating income | $m | [(4.2) d](/filings/0001410578-24-002100.md) | [(3.8)](/filings/0001410578-25-000126.md) | [(3.6)](/filings/0001410578-25-001320.md) | [(3.3)](/filings/0001410578-25-001814.md) | [(3.2) d](/filings/0001104659-25-123342.md) | [(3.0)](/filings/0001104659-26-014324.md) | [(3.4)](/filings/0001104659-26-062596.md) | [(3.7)](/filings/0001104659-26-095910.md) | [(6.0) d](/filings/0001104659-25-123342.md) | [(18.7)](/filings/0001104659-26-014324.md) | [(6.8)](/filings/0001104659-26-062596.md) | [(3.2)](/filings/0001104659-26-095910.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0 d](/filings/0001410578-24-002100.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(3.6) d](/filings/0001410578-24-002100.md) | [(1.1)](/filings/0001410578-25-000126.md) | [(4.5)](/filings/0001410578-25-001320.md) | [1.9](/filings/0001410578-25-001814.md) | [(3.3) d](/filings/0001104659-25-123342.md) | [(2.6)](/filings/0001104659-26-014324.md) | [(3.3)](/filings/0001104659-26-062596.md) | [(3.9)](/filings/0001104659-26-095910.md) | [(5.3) d](/filings/0001104659-25-123342.md) | [(18.6)](/filings/0001104659-26-014324.md) | [(6.7)](/filings/0001104659-26-062596.md) | [(4.7)](/filings/0001104659-26-095910.md) |
| Diluted EPS | $ per share | not reported | [(1.73)](/filings/0001410578-25-000126.md) | [(265.45)](/filings/0001410578-25-001320.md) | [1170.48](/filings/0001410578-25-001814.md) | not reported | [(417.53)](/filings/0001104659-26-014324.md) | [(230.30)](/filings/0001104659-26-062596.md) | [(34.00)](/filings/0001104659-26-095910.md) | not reported | [(2.08)](/filings/0001104659-26-014324.md) | [(0.68)](/filings/0001104659-26-062596.md) | [(0.57)](/filings/0001104659-26-095910.md) |
| Basic EPS | $ per share | not reported | [(1.73)](/filings/0001410578-25-000126.md) | [(265.45)](/filings/0001410578-25-001320.md) | [1170.48](/filings/0001410578-25-001814.md) | not reported | [(417.53)](/filings/0001104659-26-014324.md) | [(230.30)](/filings/0001104659-26-062596.md) | [(34.00)](/filings/0001104659-26-095910.md) | not reported | [(2.08)](/filings/0001104659-26-014324.md) | [(0.68)](/filings/0001104659-26-062596.md) | [(0.57)](/filings/0001104659-26-095910.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | period not labelled (2024-11-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.4](/filings/0001410578-24-000021.md) | [3.1](/filings/0001410578-24-000733.md) | [10.4](/filings/0001410578-24-001226.md) | [5.9](/filings/0001104659-25-123342.md) | [10.1](/filings/0001410578-24-002100.md) | [9.3](/filings/0001410578-25-000126.md) | [6.8](/filings/0001410578-25-001320.md) | [4.7](/filings/0001410578-25-001814.md) | [1.7](/filings/0001104659-26-095910.md) | [2.5](/filings/0001104659-26-014324.md) | [0.9](/filings/0001104659-26-062596.md) | [3.8](/filings/0001104659-26-095910.md) |
| Current assets | $m | [4.6](/filings/0001410578-24-000021.md) | [4.4](/filings/0001410578-24-000733.md) | [11.8](/filings/0001410578-24-001226.md) | [8.0](/filings/0001104659-25-123342.md) | not reported | [11.3](/filings/0001410578-25-000126.md) | [8.4](/filings/0001410578-25-001320.md) | [5.6](/filings/0001410578-25-001814.md) | [2.2](/filings/0001104659-26-095910.md) | [5.1](/filings/0001104659-26-014324.md) | [2.7](/filings/0001104659-26-062596.md) | [5.5](/filings/0001104659-26-095910.md) |
| Total assets | $m | [9.9](/filings/0001410578-24-000021.md) | [9.2](/filings/0001410578-24-000733.md) | [16.7](/filings/0001410578-24-001226.md) | [12.8](/filings/0001104659-25-123342.md) | not reported | [16.0](/filings/0001410578-25-000126.md) | [13.0](/filings/0001410578-25-001320.md) | [9.9](/filings/0001410578-25-001814.md) | [4.4](/filings/0001104659-26-095910.md) | [20.7](/filings/0001104659-26-014324.md) | [13.6](/filings/0001104659-26-062596.md) | [15.0](/filings/0001104659-26-095910.md) |
| Current liabilities | $m | [2.6](/filings/0001410578-24-000021.md) | [2.6](/filings/0001410578-24-000733.md) | [3.0](/filings/0001410578-24-001226.md) | [2.4](/filings/0001104659-25-123342.md) | not reported | [2.4](/filings/0001410578-25-000126.md) | [1.9](/filings/0001410578-25-001320.md) | [2.0](/filings/0001410578-25-001814.md) | [2.5](/filings/0001104659-26-095910.md) | [2.2](/filings/0001104659-26-014324.md) | [1.5](/filings/0001104659-26-062596.md) | [0.9](/filings/0001104659-26-095910.md) |
| Total liabilities | $m | [5.8](/filings/0001410578-24-000021.md) | [9.4](/filings/0001410578-24-000733.md) | [4.5](/filings/0001410578-24-001226.md) | [3.8](/filings/0001104659-25-123342.md) | not reported | [3.4](/filings/0001410578-25-000126.md) | [2.8](/filings/0001410578-25-001320.md) | [2.9](/filings/0001410578-25-001814.md) | [2.5](/filings/0001104659-26-095910.md) | [2.2](/filings/0001104659-26-014324.md) | [1.5](/filings/0001104659-26-062596.md) | [2.0](/filings/0001104659-26-095910.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [4.2](/filings/0001410578-24-000021.md) | [(0.0)](/filings/0001410578-24-000733.md) | [12.4](/filings/0001410578-24-001226.md) | [9.1](/filings/0001104659-25-123342.md) | not reported | [12.8](/filings/0001410578-25-000126.md) | [10.5](/filings/0001410578-25-001320.md) | [7.3](/filings/0001410578-25-001814.md) | [2.3](/filings/0001104659-26-095910.md) | [18.8](/filings/0001104659-26-014324.md) | [12.5](/filings/0001104659-26-062596.md) | [9.5](/filings/0001104659-26-095910.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,680) d](/filings/0001410578-24-002100.md) | [(3,758)](/filings/0001410578-25-000126.md) | [(3,210) d](/filings/0001410578-25-001320.md) | [(3,495) d](/filings/0001410578-24-001226.md) | [(3,249) d](/filings/0001410578-24-002100.md) | [(3,326)](/filings/0001410578-25-000126.md) | [(3,185) d](/filings/0001410578-25-001320.md) | [(2,631) d](/filings/0001104659-26-095910.md) | [(3,101) d](/filings/0001104659-25-123342.md) | [(5,545)](/filings/0001104659-26-014324.md) | [(2,050) d](/filings/0001104659-26-062596.md) | [(983) d](/filings/0001104659-26-095910.md) |
| Capital expenditure | $k | [(0.1) d](/filings/0001410578-24-002100.md) | not reported | not reported | [21.8 d](/filings/0001410578-25-001814.md) | [371 d](/filings/0001104659-25-123342.md) | [117](/filings/0001104659-26-014324.md) | [185 d](/filings/0001104659-26-062596.md) | [10.9 d](/filings/0001104659-26-095910.md) | [0.0 d](/filings/0001104659-25-123342.md) | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities, us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [12.9](/filings/0001410578-24-000021.md) | [0.6](/filings/0001410578-24-000733.md) | [0.6](/filings/0001410578-24-001226.md) | [0.7](/filings/0001410578-25-000126.md) | [0.0](/filings/0001410578-25-001320.md) | [0.0](/filings/0001410578-25-001814.md) | [0.0](/filings/0001104659-26-014324.md) | [0.1](/filings/0001104659-26-062596.md) | [0.6](/filings/0001104659-26-095910.md) | [8.9](/filings/0001104659-26-014324.md) | [9.7](/filings/0001104659-26-062596.md) | [8.4](/filings/0001104659-26-095910.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 6,197,223 at 2026-08-12, from the cover of the [10-Q filed 2026-08-13](/filings/0001104659-26-095910.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.